At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 61 enrolled
Drug / intervention
Granulocyte-colony stimulating factor (G-CSF) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
In Brief
A Phase 4 clinical trial evaluating Granulocyte-colony stimulating factor (G-CSF), Fixed Dose Plerixafor, and 1 other intervention for Non-Hodgkin's Lymphoma. Completed, enrolled 61 participants across 7 sites in 4 countries.
Detailed Summary
The purpose of this study was to compare the responses of 2 different doses of plerixafor in patients with Non-Hodgkin's Lymphoma (NHL) who received an autologous stem cell transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma
CountriesCanada, South Korea, Taiwan, United States
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartOct 2010
Primary CompletionFeb 2013
TodayJul 2026
First PostedJul 16, 2010
Enrollment StartOct 1, 2010
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.0 years ago
Interventions
Granulocyte-colony stimulating factor (G-CSF)drug
Fixed Dose Plerixafordrug
Weight-Based Plerixafordrug